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Zebrafish studies identify serotonin receptors
mediating antiepileptic activity in Dravet
syndrome
Aliesha L. Griffin,1 Priyadarshini Jaishankar,2 Jean-Marc Grandjean,3 Steven H. Olson,3
Adam R. Renslo2 and Scott C. Baraban1
Dravet syndrome is a life-threatening early-onset epilepsy not well controlled by antiepileptic drugs. Drugs that modulate serotonin
(5-HT) signalling, including clemizole, locaserin, trazodone and fenfluramine, have recently emerged as potential treatment options
for Dravet syndrome. To investigate the serotonin receptors that could moderate this antiepileptic activity, we designed and synthe-
sized 28 novel analogues of clemizole, obtained receptor binding affinity profiles, and performed in vivo screening in a scn1lab mu-
tant zebrafish (Danio rerio) model which recapitulates critical clinical features of Dravet syndrome. We discovered three clemizole
analogues with 5-HT receptor binding that exert powerful antiepileptic activity. Based on structure–activity relationships and medi-
cinal chemistry-based analysis, we then screened an additional set of known 5-HT receptor specific drug candidates. Integrating
our in vitro and in vivo data implicates 5-HT2B receptors as a critical mediator in the mechanism of seizure suppression observed
in Dravet syndrome patients treated with 5-HT modulating drugs.
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Introduction
The discovery of antiepileptic drugs (AEDs) has tradition-
ally relied upon acute seizure models in adult rodents.
Unfortunately, this approach does not incorporate genetic
epilepsies like those associated with de novo gene muta-
tions and classified as catastrophic childhood epileptic
encephalopathies (Lo¨scher, 2017a,b). In vivo drug discov-
ery and development using phenotype-based screening in
genetically modified larval zebrafish (Danio rerio) offer a
promising ‘precision medicine’ focused alternative
(Baraban et al., 2013; Dinday and Baraban, 2015;
Griffin et al., 2016; Grone et al., 2017). Drug candidates
identified using in vivo screens provide valuable biologic-
al context and offer a more successful route to clinical
implementation. As an example, about 62% of first-in-
class small molecules registered by the Food and Drug
Administration between 1999 and 2008 had their origin
in a phenotype-based approach compared to only 38%
in target-based drug discovery (Swinney and Anthony,
2011). Zebrafish are uniquely suited to phenotype-based
in vivo drug discovery programs and are highly amenable
to the study of structure–activity relationships that repre-
sent a critical step in the drug development process (Zon
and Peterson, 2005).
Dravet syndrome is a medically refractory catastrophic
epileptic encephalopathy. Patients typically exhibit
frequent episodes of prolonged seizures before the age of
one (Dravet, 2011), and have an increased risk of
Sudden Unexplained Death in Epilepsy (Cooper et al.,
2016). The majority of Dravet syndrome patients are
identified with de novo mutations within the SCN1A
gene resulting in haploinsufficiency of a neuronal voltage-
gated sodium channel (Catterall et al., 2010; Escayg and
Goldin, 2010; Dravet and Oguni, 2013). Current Food
and Drug Administration-approved antiepileptic drugs are
unable to provide adequate seizure control in this patient
population. The lack of effective seizure control using
available antiepileptic drugs has resulted in a significant
effort to discover and develop new treatment options for
these patients (Ziobro et al., 2018). Although genetically
modified mouse models and induced pluripotent stem cell
derived neurons exist to model features of Dravet syn-
drome, large-scale drug discovery and development in
these systems is lacking. As an alternative, larval zebra-
fish with a mutation in the SCN1A homologue, scn1lab,
display persistent spontaneous electrographic seizures and
convulsive swim behaviours, as early as 3 days post-fertil-
ization (Baraban et al., 2013). Importantly, these spon-
taneous seizures in scn1lab mutant zebrafish exhibit
pharmaco-resistance to 13 antiepileptic drugs (Baraban
et al., 2013; Ziobro et al., 2018). As such, this zebrafish
model faithfully mimics the epileptic phenotype observed
in Dravet syndrome patients. Using scn1lab zebrafish and
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a two-stage in vivo phenotype-based platform, blind
screening of more than 3500 compounds identified sero-
tonin (5-HT) receptor agonists (clemizole, trazodone and
lorcaserin) and a serotonin reuptake inhibitor (fenflur-
amine) as potential new Dravet syndrome therapies
(Baraban et al., 2013; Dinday and Baraban, 2015;
Sourbron et al., 2016; Griffin et al., 2017). Furthermore,
limited clinical studies of lorcaserin (Griffin et al., 2017;
Tolete et al., 2018), trazodone (Kauppila et al., 2018),
and fenfluramine (Ceulemans et al., 2012; Ceulemans
et al., 2016; Schoonjans et al., 2017) have demonstrated
anti-seizure activity in Dravet syndrome patients.
Serotonin receptors (5-HTR) represent a group of G-
protein coupled receptors and ligand-gated ion channels
found in the central and peripheral nervous system
(Barnes and Sharp, 1999). 5-HTRs can be divided into
seven subtypes, with subunits 5-HT1–7 receptors
expressed in neurons of the central nervous system, and
5-HT1AR, 5-H2AR and 5-H2BR also present on astrocytes
(Carson et al., 1996; Zhang et al., 2010; Miyazaki and
Asanuma, 2016). Since the 1970s, there has been a grow-
ing body of evidence to implicate 5-HT with seizure sus-
ceptibility; however, the precise mechanism remains
elusive. Increased brain 5-HT was reported to reduce the
severity of audiogenic- and chemoconvulsant-induced seiz-
ures (De la Torre et al., 1970; De la Torre and Mullan,
1970), as well as increase the threshold to electroshock-
induced seizures (Kilian and Frey, 1973). More recently,
5-HT2CR knockout mice show spontaneous seizures, pre-
mature death (Tecott et al., 1995) and are more sensitive
to electroshock- or chemoconvulsant-induced seizure pro-
tocols (Applegate and Tecott, 1998). Furthermore, studies
in DBA/2 mice support a role for 5-HTR modulation in
Sudden Unexplained Death in Epilepsy (Tupal and
Faingold, 2006; Uteshev et al., 2010).
Here, we report a structure–activity relationship study
designed to test the hypothesis that 5-HTRs are a critic-
al site of action for drugs showing anti-seizure activity
in Dravet syndrome patients. We synthesized 28 novel
clemizole analogues (clemalogues) with varying 5-HT2R
binding affinities and identified three clemalogues exert-
ing a powerful suppression of convulsive swim behav-
iour and electrographic seizure activity in scn1lab
zebrafish. Based on these 5-HT2R properties, a medicin-
al chemistry structure–activity relationship-based ana-
lysis led to a second round of screening, and
identification of two 5-HT2BR agonists (methylergono-
vine and 6-(2-aminopropyl)benzofuran (6-APB)) that
also suppressed convulsive swim behaviour and electro-
graphic seizure activity. Taken together, these findings
have implications for the mechanism of action of 5-
HT2R modulating drugs (i.e. clemizole, lorcaserin, tra-
zodone and fenfluramine) currently in clinical develop-
ment for Dravet syndrome (Knupp and Wirrell, 2018;
Ziobro et al., 2018) and for future research into how
5-HT signalling may influence seizure activity.
Materials and methods
Chemical synthesis and compounds
Initially, clemizole analogues were synthesized in house at
the UCSF Small Molecule Discovery Center for functional
testing. Select compounds were also synthesized independ-
ently by Oxygen Healthcare Research Pvt. Ltd. for con-
firmation purposes using the same UCSF methodology
outlined. Chemical reagents and solvents used here are
commercially available, unless stated otherwise. For all
air and/or moisture sensitive reactions experiments were
performed under an argon atmosphere using oven-dried
glassware and commercially available anhydrous solvents.
All reagents that were deemed air and/or moisture sensi-
tive were transferred via syringe or cannula through rub-
ber septa into the reaction vessel. A rotary evaporator,
set to ca. 10–50Torr, was used for solvent removal. A
Varian INOVA-400 400MHz spectrometer was used to
measure 1H nuclear magnetic resonance (NMR) spectra
and reported in d units (ppm). NMR spectra were refer-
enced relative to residual NMR solvent peaks and cou-
pling constants (J) are reported in hertz (Hz). A CEM
Discover microwave reactor was used to carry out micro-
wave reactions. An Isolera Four flash chromatography
system and SiliaSep silica gel cartridges (Silicycle) were
used for column chromatography. A Waters Micromass
ZQ mass spectrometer equipped with Waters 2795
Separation Module, Waters 2424 Evaporative Light
Scattering Detector, and Waters 2996 Photodiode Array
Detector was used to acquire liquid chromatography/mass
spectrometry data. Separations were performed on a
XTerraV
R
MS C18, 5mm, 4.6  50mm column, at ambi-
ent (unregulated) temperature using a mobile phase of
water–methanol containing 0.1% formic acid. Details of
synthesis steps for each distinct synthetic route employed
are described in the Supplementary material.
Compounds were commercially sourced from Millipore
Sigma [Methylergonovine maleate, BW-723C86, 1-(3-
chlorophenyl)piperazine hydrochloride (m-CPP), (þ)-
Norfenfluramine hydrochloride], Cayman Chemicals
[Cabergoline, Bromocriptine mesylate, ()-Apomorphine
hydrochloride], ApexBio (Ro 60-0175 fumarate), Tocris
Bioscience (CP-809, 101 hydrochloride), AK Scientific,
Inc. (Piribedil) and Axon Medchem (TL 99 hydrobro-
mide). Ten millimolars of compound stock solutions were
made in dimethyl sulfoxide and then diluted in embryo
medium for assays.
Zebrafish maintenance
Zebrafish (D. rerio) was maintained in our zebrafish fa-
cility on a 14/10 h light dark cycle. Experimental proce-
dures followed the Guide for the Care and Use of
Animals (ebrary Inc. 2011) and were approved by the
Institutional Animal Care and Use Committee (protocol #
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AN108659-03). Embryos were obtained by natural
spawning of adult heterozygous scn1lab (didys552) ani-
mals maintained on a Tubingen long fin strain back-
ground. Starting at 3 days post-fertilization homozygous
scn1lab mutants (n¼ 2500) appear visibly darker than
age-matched wild-type larvae.
Seizure monitoring
For locomotion studies, zebrafish larvae (5 days post-fer-
tilization) were placed into a single well of a clear flat-
bottomed 96-well microplate containing embryo media.
Sex determination is not possible at this stage of develop-
ment. All drug screening experiments were conducted in
an unbiased manner by investigators blinded to the test
compounds and all files coded for post hoc analysis. The
96-well plate containing larvae was then placed inside a
DanioVision box where they were allowed to acclimate
(20min; room temperature). EthoVision XT software
(DanioVision, Noldus Information Technology) was used
to obtain locomotion plots (10min in duration). Seizure
scoring was performed, as described (Baraban et al.,
2005). All locomotion plots were analysed for distance
travelled (in millimetres) and mean velocity (in millimetres
per second). After 90 min of drug exposure larvae were
examined for toxic side-effects. Compounds that
decreased or stopped the larva heartbeat, or reduced or
eliminated the escape response when touched, were con-
sidered toxic.
For electrophysiology studies, zebrafish larvae were
anaesthetized with cold by placing at 4C for 5 min until
no movement was observed and then immobilized in
1.2% agarose dorsal side up. Using a glass micro-elec-
trode positioned under an upright microscope, local field
potential (LFP) recordings were obtained from forebrain
or optic tectum structures, as described (Baraban et al.,
2005). Agarose-embedded LFP recording sessions (10min
in duration) were obtained using Axoclamp software
(Molecular Devices; Sunnyvale, CA, USA) and sampled at
1 kHz. Epileptiform events were identified post hoc.
These were classified as multi-spike or poly-spike upward
or downward membrane deflections greater than 3
baseline noise level and 150–250ms in duration (interic-
tal-like) or greater than 5 baseline noise, multi-spike
and >500ms in duration (ictal-like); both events were
counted using threshold detection settings in Clampfit
(Molecular Devices; Sunnyvale, CA, USA). Agarose-
embedded larvae were continuously monitored for blood
flow and heart rate using an Axiocam digital camera at
video frame rate.
Receptor binding assays
All in vitro binding assay and Ki data studies were per-
formed by the US National Institute of Mental Health
Psychoactive Drug Screening Program (NIMH PDSP). For
these studies, drugs were screened against recombinant,
stably expressed human 5-HT2AR, 5-HT2BR, 5-HT2CR
and H1, as described at https://pdspdb.unc.edu/pdspWeb/
(Besnard et al., 2012).
Statistical analysis
For behaviour analysis, the threshold for a change in mean
swim velocity 40% is considered significant (>1.5 SD
of 250 control treated scn1lab). Unless otherwise indicated,
all data in this manuscript are presented as the mean 6
standard error of the mean. For comparison between more
than two groups a one-way analysis of variance test was
performed. n the A non-parametric Kruskal–Wallis test was
used followed by Dunns multiple comparison test for vari-
ance data that did not exhibit a normal distribution.
Statistically significant differences are indicated with aster-
isks (*P< 0.05; **P< 0.01; ***P< 0.001).
Data availability statement
The authors confirm that the data supporting the findings
of this study are available within the article and
Supplementary material.
Results
Design, synthesis and whole-
organism screening of clemizole
analogues
To identify a key pharmacophore responsible for sup-
pressing seizure activity in Dravet syndrome zebrafish, we
began with structural optimization of the hit compound
clemizole hydrochloride, a first-generation antihistamine
shown to inhibit seizures in this model (Baraban et al.,
2013). We systematically modified both the benzyl and
pyrrolidine side chains in clemizole, as well as the benzi-
midazole core (Fig. 1). Twenty-eight analogues were pre-
pared, in 1–3 steps, using one of the six synthetic routes
shown (Fig. 2 and Supplementary Table S1).
Using the established phenotypic-based screening plat-
form (Baraban et al., 2013), and the previously deter-
mined concentration range of the parent compound
clemizole (Griffin et al., 2017), we tested the 28 clemizole
analogues for their ability to reduce mean swim velocity
of 5 days post-fertilization scn1lab mutants at a concen-
tration of 100 mM or 250 mM (six fish per drug treat-
ment). As the initial analogue screening identified non-
basic compounds 1 and 2 as toxic, we focused further
efforts on analogues that retained the pyrrolidine side
chain, or that bore a similar heterocyclic ring with a
basic amine. A total of seven such analogues were pre-
pared, among which analogues 22, 23 and 27 bearing
six-membered heterocyclic rings as well as acyclic dime-
thylamino analogue 24 were found to be toxic. In total,
five compounds (17.9%) were identified as toxic at
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100 mM, which increased to 12 compounds (42.9%) at
250 mM. Subsequent modification of the 4-chlorophenyl
ring, or replacement with cycloalkyl ring surrogates
resulted in better tolerance in the zebrafish assay,
affording several active analogues and few with any not-
able toxicity, as detailed below.
The clemizole analogues 4, 6, 9 and 20 were effective in
suppressing the scn1lab mutant seizure-like behaviour at
Figure 1 Structure of clemizole and clemalogues 1–28. Chemical structure of clemizole and 28 clemizole analogues synthesized as part
of SAR studies detailed herein. Sites of modification to the clemizole structure are highlighted in blue for each clemalogue subtype shown. Full
chemical structures are provided in Supplementary Table S1.
Figure 2 Synthesis of clemalogues. Summary of synthetic routes used to prepare clemalogues 1–28. (a) cyclopentylacetic acid,
PPA, lw, 80C, 20%; (b) ClCH2(4-ClPh), K2CO3, DMF, 60C, 67%; (c) ethyl 4-Cl-3-oxobutanoate, SnCl2, EtOH, 80C; (d) pyrrolidine, EtOH,
95C; 83% for two steps (e) Br-CH2R, NaH, THF, 0C to rt, 15–60% or Br-CH2R, NaH, TBAI, THF, 0C to rt, 13–54% or propyl iodide, NaH,
THF, 0C to rt, 47%;(f) p-Cl-benzylchloride, NaH, DMF, rt, 54%; (g) (i) LiOH, MeOH/water, rt, (ii) pyrrolidine, HATU, DIEA, DMF, rt, 43% over 2
steps; (h) p-Cl-benzylchloride, K2CO3, CH3CN, 45
C, 85% or cyclohexylmethyl bromide, K2CO3, TBAI, CH3CN, 55C, 30%; (i) pyrrolidine,
Na(OAc)3BH, CH2Cl2; 30–46%; (j) ClCH2Ar, K2CO3, CH3CN, 45
C, 44%; (k) pyrrolidine, Na(OAc)3BH, CH2Cl2, rt, 65%; (l) HNR2,
Na(OAc)3BH, CH2Cl2, rt, 47–85%; (m) H2, Pd/C, MeOH, rt, 55%; (n) 4M HCl in dioxane, rt.
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100mM or 250mM, respectively (Fig. 3). To confirm the
anti-seizure effect on convulsive behaviours of scn1lab
mutants, clemizole analogues 4, 6, 9 and 20 were synthe-
sized independently (by Oxygen Healthcare Research Pvt.
Ltd.) using the same methodology as described. Newly
synthesized compounds were retested at 10, 50, 100 and
250mM to confirm a concentration-dependent response.
Clemizole analogues 4, 6 and 20 reduced the high-velocity
seizure-like swim behaviour observed in the scn1lab mu-
tant zebrafish larvae, confirming the initial screening
Figure 3 Phenotypic screening of clemizole analogues. Twenty-eight clemizole analogues were screened for efficacy in suppressing the
high-velocity seizure-like swim behaviour observed in scn1lab mutant zebrafish. Plots show the change in mean swim velocity of 5 dpf larvae
screened at (a) 100mM, or (b) 250 mM. Threshold for inhibition of seizure activity (positive hits—yellow data points) was determined as a
reduction in mean swim velocity of 40% (red dashed line). The red data points represent compounds that were classified as toxic after 90-min
exposure. The heat map shows the % change in velocity for the six individual larva from the first trial (1–6). Mean velocity change from six
individual fish is shown for trial 1 and 2. Clemizole analogue 25 (*) failed to go into solution at 250 mM so it was not considered for further
testing.
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results with analogues synthesized at UCSF (Fig. 4). The
resynthesized compound 9 was toxic at 250mM. This con-
firmed the result from the second testing of the original
compound and suggests the decrease in swim behaviour
observed during trial 1 may be a false positive result.
Overall, this preliminary structure–activity relationship
study revealed the importance of the pyrrolidine side chain
in mitigating toxicity and suggests the side chain at N1 of
the benzimidazole (or imidazole) core as a promising av-
enue for further lead optimization of this chemotype.
Figure 4 Evaluation of clemizole analogues that reduce seizure-like swim behaviour in scn1lab mutant zebrafish. Clemizole
analogues identified as positive from the in vivo screen were freshly synthesized and retested for efficacy in suppressing the
seizure-like swimming behaviour of 5 dpf scn1Lab mutant zebrafish. Graphs show the change in mean velocity over four
concentrations of (a) compound 4, (b) compound 6 and (c) compound 20. Each bar represents the mean change in velocity 6 SEM from three
independent experiments (six individual larva per experiment). Toxicity is indicated by dashed bars. The threshold for a decrease in velocity is
40% (red line). Locomotion of larvae was recorded for 10min after an exposure of 30min (blue bars) and 90min (yellow bars). A
representative raw 10min tracking plot is shown for a single experiment of six individual scn1Lab zebrafish. The chemical structure for each
clemizole analogue is shown (d–f). In vitro radioligand binding analyses of (g) compound 4, (h) compound 6 and (i) compound 20 revealed
specificity for 5-HT2BR over 5-HT2R subtypes. SB206553 was used as a positive control for 5-HT2BR binding (black). The binding affinity for the
other clemizole analogues is given in Supplementary Table S2.
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Clemizole analogues with
anti-seizure activity selectively bind
5-HT2BR
From our library of clemizole analogues, we identified
three compounds which suppress the convulsive high-vel-
ocity swim behaviour observed in the scn1lab Dravet syn-
drome zebrafish model. The parent compound clemizole
hydrochloride has previously been reported to have agon-
ist activity for 5-HT2AR and 5-HT2BR (Griffin et al.,
2017). Additionally, 5-HT2R modulating compounds
exert antiepileptic activity in both preclinical (Sourbron
et al., 2016; Griffin et al., 2017) and clinical studies
(Griffin et al., 2017; Schoonjans et al., 2017; Kauppila
et al., 2018). Therefore, we determined 5-HT2R binding
affinities for 21 of the clemizole analogues using the
radioligand binding assays performed blinded by the
NIMH Psychoactive Drug Screening Program (Besnard
et al., 2012). Our three hit compounds, 4, 6 and 20, had
significant preference for 5-HT2BR with Ki values of
612 nM, 285 nM and 772 nM, respectively (Fig. 4;
Supplementary Table S2). Additionally, these clemizole
analogues showed no significant binding to 5-HT2AR or
5-HT2CR (Ki >10 000 nM). Retrospectively, we observed
compounds 5, 14 and 23 also show selectivity for 5-
HT2BR with Ki values of 219 nM, 606 nM and 515 nM.
In our initial library screen compounds 5 and 14 had no
significant effect on swim behaviour and compound 23
was identified as toxic. Additional testing of independent-
ly synthesized compound confirmed compounds 5 and 14
have no significant effect on the swim behaviour of the
scn1lab zebrafish within the constraints of our screening
assay (i.e. duration of exposure and compound concen-
tration) (Supplementary Fig. S1). Four of the 21 clemizole
analogues (compound 10, 15, 17 and 21) showed no sig-
nificant binding to any human 5-HT2R.
5-HT2BR agonists suppress seizure
activity in the scn1lab zebrafish
model
Structure–activity relationship analysis using clemizole
analogues suggests 5-HT2BR may contribute to the
observed anti-seizure activity in scn1lab zebrafish. Next,
we tested a series of commercially available compounds
known to bind 5-HT2BR (Roth et al., 2000) for their
ability to reduce the seizure-like swim behaviour of the
scn1lab zebrafish larvae (Supplementary Table S3). Three
5-HT2BR agonists, methylergonovine, 6-APB and norfen-
fluramine suppressed convulsive swim behaviours in a
concentration-dependent manner (Fig. 5). Additionally,
scn1lab mutant larvae treated with 5-HT2BR agonist BW-
723C86, showed a decrease in seizure-like swim behav-
iour, but also failed to reach our significance threshold to
warrant further testing. This confirms previous observa-
tions for the 5-HT2BR agonist BW-723C86 (Sourbron
et al., 2016). Similarly, the 5-HT2BR/5-HT2CR agonist
Ro60-0175 consistently decreased mean velocity and was
borderline effective after 90 min of drug exposure.
Treatment with CP-809, 101 gave a biphasic response, as
did m-CPP, the active metabolite of trazodone, confirm-
ing behavioural responses observed in other model sys-
tems (Yonezawa et al., 2008). TL-99, which had the
lowest affinity for 5-HT2Rs, failed to elicit any behav-
ioural effect in scn1lab mutant larvae in our assay
(Fig. 5f).
Dopamine receptor agonists with reported 5-HT2R
were also tested for their ability to reduce seizure-like
swim behaviour (Supplementary Fig. S2). Cabergoline, a
dopamine agonist with recognized high affinity for acti-
vating 5-HT2BR (Ki ¼ 1.2 nM) significantly reduced con-
vulsive swim behaviour at 250 mM; however, due to the
lack of a concentration-response it did not undergo fur-
ther testing. Bromocriptine significantly reduced seizure-
like swim behaviour at 10 mM; however, toxicity was
observed at higher concentrations. Piribedil, a dopamine
2 receptor agonist (Ki ¼ 1.3 nM), also showed toxicity at
100 and 250 mM and the non-selective dopamine agonist,
apomorphine, significantly increased mean swim velocity
of scn1lab mutant larvae, an effect which is also seen in
wild-type zebrafish larvae (Ek et al., 2016).
Monitoring electrographic brain activity to confirm seiz-
ure suppression is an essential assay to eliminate false pos-
itives from behavioural testing (Griffin et al., 2018). By
placing a micro-electrode into a visually identified brain re-
gion of an agar-immobilized zebrafish larval, stable LFP
recordings can be monitored for several hours (Baraban,
2013). At 5 days post-fertilization, LFP recordings of
scn1Lab zebrafish larvae show an average of 250 abnor-
mal electrographic seizure events during a 10min record-
ing epoch. LFP recordings of scn1lab mutants confirmed
significant suppression of electrographic seizure activity
after exposure to clemizole analogues 4, 6 and 20 at
100mM. Representative LFP recording epochs with only
the occasional abnormal electrographic event are shown in
Fig. 6. Similarly, 250mM methylergonovine (n¼ 7;
P< 0.001) or 250mM 6-APB (n¼ 6; P ¼ 0.0238) signifi-
cantly suppressed the frequency of electrographic seizure
events in a manner similar to the 5-HT2BR selective clemi-
zole analogues 4, 6 and 20. Radioligand binding data for
methylergonovine, 6-APB and the positively identified
clemizole analogues 4, 6 and 20, suggest that all five com-
pounds share a binding affinity for 5-HT2BR (Table 1).
Discussion
The 5-HT modulating compounds, clemizole, lorcaserin,
trazodone and fenfluramine are currently in clinical devel-
opment for Dravet syndrome. Focusing on clemizole as a
promising screening hit, we performed structural–activity–
relationship studies to identify targets required for antiepi-
leptic activity. By generating novel clemalogues, we
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Figure 5 Dose response evaluation of 5HT2BR agonists in scn1lab mutant zebrafish. 5HT2BR agonists were tested for efficacy
in reducing the high-speed seizure-like behaviour in 5 dpf scn1lab mutant zebrafish. Graphs show the change in mean velocity over
three concentrations of (a) methylergonovine, (b) 6-APB, (c) norfenfluamine, (d) BW-723C86, (e) RO-60-0175, (f) TL-99, (g) m-CPP and (h)
CP-809, 101. Larvae locomotion was recorded for 10min after an exposure of 30min (blue bars) and 90min (yellow bars). Each bar represents
the mean change in velocity6 SEM from three independent experiments (six individual larva per experiment). The threshold for a decrease in
velocity is 40% (red line). Representative tracking plots of a 10min recording are shown for six individual 5 dpf scn1lab zebrafish at baseline,
and following 30min and 90min exposure of 100 mM of each compound.
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determined that compounds capable of suppressing spon-
taneous seizures in vivo had a binding preference to 5-
HT2BR. Additionally, we present pharmacological data
which suggest that activation of 5-HT2BR may be the
common antiepileptic mechanism of action shared by the
5-HT modulating compounds showing efficacy in clinical
trials and validated preclinical models of Dravet syndrome.
Our approach used an iterative medicinal chemistry
process involving the analysis of the chemical structure of
clemizole, generating novel analogues of this compound,
and using target-engagement assessment through a series
of in vivo and in vitro assays. As a low-cost and efficient
alternative to typical experimental animals, this zebrafish-
based strategy can be considered a novel disruptive tech-
nology in the field of antiepileptic drug discovery. While
we are not suggesting that zebrafish replace mammalian
models, these findings can be taken as validation of our
zebrafish-based approach, as lorcaserin (Belviq; EPX-
200), trazodone (EPX-300) and fenfluramine (ZX-008)
are already showing clinical anti-seizure efficacy in
Dravet syndrome patients (Ceulemans et al., 2012;
Ceulemans et al., 2016; Griffin et al., 2017; Schoonjans
et al., 2017; Kauppila et al., 2018; Tolete et al., 2018).
Our laboratory has completed blinded phenotype-based
screening of over 3500 compounds in a Dravet syndrome
zebrafish model (Griffin et al., 2018). This screening
Figure 6 Electrophysiological assay to identify drugs that rescue the scn1lab mutant epilepsy phenotype. (a) Electrophysiology
recording were obtained with an electrode placed in the forebrain of 5 dpf agar-immobilized scn1lab larvae that had previously showed
suppressed seizure-like behaviour in the locomotion assay. (b) Bar graphs show the frequency of epileptiform events in a 10min recording epoch
for scn1lab larvae exposed to clemizole analogues 4 (n¼ 15), 6 (n¼ 12), 20 (n¼ 9), 6-APB (n¼ 6), norfenfluramine (NorFA) (n¼ 8),
methylergonovine (MeERGO) (n¼ 7) or scn1lab mutants (n¼ 15). The graph represents mean 6 SEM and individual data points are shown.
Kruskal–Wallis one-way analysis of variance was used to test for significance. *P< 0.05; **P< 0.01; ***P< 0.001. (c) Representative field
electrode recording epochs (10min) are shown for clemizole analogues 4, 6, 20, methylergonovine (MeERGO) and 6-APB. These compounds
showed significant changes in the frequency of events compared to untreated scn1lab mutant zebrafish (red).
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platform has spanned multiple drug classes targeting sev-
eral suggested therapeutic mechanisms. Importantly, a
common feature of the small number of compounds iden-
tified as capable of suppressing spontaneous seizure activ-
ity in this assay (<0.2% of all compounds screened; i.e.
clemizole, lorcaserin and trazodone), appears to be a
binding affinity for 5HT2R subtypes. Here, we identified
three novel clemizole analogues and two additional com-
mercially available compounds that mimic the suppression
of seizure activity seen previously. These findings support
a working hypothesis that targeting a combination of, or
a single, 5HT2R is therapeutic for Dravet syndrome.
Similar to how most of the present antiepileptic drugs
have been discovered and studied, these findings are lim-
ited to the pharmacological tools available and will, ul-
timately, require molecular and/or functional strategies to
precisely confirm a mechanism of action. Nonetheless,
our conclusion is consistent with pharmacological and
knockout mouse studies implicating 5-HT2 receptors in
anti-seizure and anti- Sudden Unexplained Death in
Epilepsy actions (Tupal and Faingold, 2006).
The structural similarity for 5-HT2 receptors makes
developing therapeutic compounds with high receptor
subtype specificity and affinity challenging. In comparison
to the parent compound clemizole, our clemizole ana-
logues gained 5-HT2 receptor specificity but decreased re-
ceptor affinity. Therefore, these analogues provide a
useful tool for understanding the mechanism of the anti-
seizure action of clemizole. In addition to receptor sub-
type similarity, 5-HT2R agonists may have functional se-
lectivity, whereby, a ligand can preferentially activate one
receptor-linked intracellular signalling pathway (i.e., Gq-
linked calcium flux or b-arrestin recruitment). While the
signalling bias of each clemizole analogue remains to be
determined, methylergonovine is known to have a strong
preference for activating the b-arrestin pathway (Wacker
Table 1 Receptor specificity and binding affinity (Ki) for compounds effective in suppressing spontaneous seizure ac-
tivity in scn1lab mutant zebrafish
MeERGO, methylergonovine; CLEM, clemizole; TRAZ, trazodone; LOR, lorcaserin; FEN, fenfluramine. Compounds in yellow represent significant binding to the receptor target.
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et al., 2013). As methylergonovine is capable of reducing
seizures in the scn1lab larvae, functional signalling may
be an additional consideration when determining the
mechanism of antiepileptic action shared between these
serotonin modulating compounds.
Within the field of drug development, 5-HT2BR agonist
activity has sometimes been perceived as negative due to
the putative involvement of this receptor subtype in heart
valve pathogenesis (Roth, 2007; Papoian et al., 2017).
Indeed, activation of 5-HT2BR can induce a mitogenic ef-
fect on valvular endothelial cells and has resulted in the
discontinued development of some compounds (Roth,
2007). Perhaps one of the most recognizable compounds
to be withdrawn under Food and Drug Administration
recommendation is the 5-HT reuptake blocker fenflur-
amine (Rothman et al., 2000), a compound currently in
clinical trial as an add-on therapy for Dravet syndrome
patients with, as yet, no reported negative cardiovascular
events (Ceulemans et al., 2012; Ceulemans et al., 2016).
Once approved as an anorectic, it was later removed
from the market after heart valve defects were noted in
25% of patients (Abenhaim et al., 1996; Khan et al.,
1998). Norfenfluramine, the active metabolite of fenflur-
amine is a potent activator of 5-HT2BR and may contrib-
ute to these observed heart valve defects (Fitzgerald
et al., 2000). In the scn1lab zebrafish Dravet syndrome
model, fenfluramine is effective in suppressing spontan-
eous seizures (Dinday and Baraban, 2015; Sourbron
et al., 2016), additionally, norfenfluramine was able to
restore the swimming behaviour or scn1lab mutant larvae
to wild-type levels (Stage I) and reduce spontaneous seiz-
ure events in some, but not all larvae (5 out of 8 larvae;
Fig. 6) suggesting that this active metabolite may contrib-
ute to the anti-seizure activity of fenfluramine.
Our previous working hypothesis proposed that clemi-
zole, lorcaserin, trazodone and fenfluramine could increase
gamma-aminobutyric acid (GABA)-mediated synaptic in-
hibition through direct activation of (i) 5-HT2ARs, which
are expressed throughout the central nervous system; or
(ii) 5-HT2CRs which are expressed on a subpopulation of
inhibitory interneurons (Liu et al., 2007). However, newly
synthesized clemalogues with selective affinity for 5-HT2A
or 5-HT2C receptor subtypes were not consistently
observed to inhibit spontaneous seizures in our zebrafish
model whereas those with 5-HT2BR binding properties
were effective. The histamine receptor (H1) is also a com-
mon site of action for clemizole (a first-generation antihis-
tamine) and many of the compounds described in this
manuscript. This receptor was excluded as the mechanism
of action site because antihistamines are often contraindi-
cated as anti-seizure medications in paediatric epilepsies
(Miyata et al., 2011). Additionally, prior screening of
more than 40 different H1-receptor binding compounds
failed to identify any other antihistamines with anti-seiz-
ure activity (Griffin et al., 2017).
Zebrafish have a single 5-HT2BR orthologue, which has
62.0% protein identity compared to the human protein
(Griffin et al., 2017). While htr2b is expressed in the
zebrafish brain (Theodoridi et al., 2017), the precise cell
type in the larval central nervous system where this recep-
tor is expressed has not been established. In the mamma-
lian brain, prominent central nervous system expression of
5-HT2BR has been reported on astrocytes (Sanden et al.,
2000; Zhang et al., 2010), and receptor activation can re-
sult in elevated calcium signalling. 5-HT2R mediated en-
hancement of astrocyte signalling could (i) release
glutamate onto GABAergic interneurons causing a potenti-
ation of inhibitory interneuron signalling (Kang et al.,
1998), or (ii) provide positive feedback autoregulation to
somatostatin-expressing GABAergic interneurons innervat-
ing the dendrites of excitatory pyramidal neurons (Matos
et al., 2018). Additionally, neuronal 5HT2BR expression
has been reported in Purkinje cells (Choi and Maroteaux,
1996) and neurons in the dorsal raphe nuclei (Diaz et al.,
2012). Optogenetic stimulation of these raphe neurons has
been shown to suppress both hippocampal and cortical
neuronal activity, as well as Sudden Unexplained Death in
Epilepsy in mice (Wang et al., 2015; Lottem et al., 2016;
Zhang et al., 2018). There is also evidence to suggest that
5-HT2B receptors directly modulate serotonin levels inde-
pendently of the serotonin transporter (Hertz et al., 2015).
Finally, published evidence for 5-HT2BR expression on
microglia (Krabbe et al., 2012; Kolodziejczak et al., 2015)
could suggest a modulatory role as part of the tripartite
synapse (Ji et al., 2013). Each of these possibilities are pre-
sented as potential mechanisms of action for discussion
purposes only and merit further investigation using the
pharmacological tools developed here.
In conclusion, our results imply a 5-HT2BR mechanism
of action for several serotonergic compounds currently in
clinical development for Dravet syndrome and suggest
that a zebrafish-based strategy may represent a promising
avenue to the discovery and development of drugs for
treating catastrophic epilepsies of childhood.
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